
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is an attractive investment opportunity due to its positive developments with the EsoGuard test and potential for market expansion and partnerships. While there are risks involved, such as reimbursement and commercial execution, the company is confident in its products and expects to see significant growth in the future, with a potential market opportunity of $2 billion in the US. Investors can expect a strong return on their investment in Lucid Diagnostics and should closely monitor the company's financials and developments in the esophageal cancer market.
Bears say
Lucid Diagnostics is a medical diagnostics technology company with a negative outlook, as evidenced by its high quarterly EBITDA loss of -$13.7 million and its consistent use of cash in its operations. Despite recent success in gaining positive coverage with some of the largest commercial health plans, there remain risks to achieving positive shareholder returns due to potential balance sheet and liquidity concerns, as well as uncertainties surrounding product efficacy, regulatory approvals, and competition in the market. Additionally, the attractiveness of Lucid's current valuation may not be enough to outweigh these risks, particularly for investors with a more cautious stance on the biotech/medtech industry.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares